Post Profile






Exenatide via Osmotic Mini-Pump Improved A1c and Weight

ITCA 650 is exenatide in an osmotic mini-pump, a type 2 diabetes medication. It continually provides subcutaneous medication for 3 to 6 months. Currently, exenatide is available as the brand name Byetta which is a liquid injection and also an extended release formulation marketed as Bydureon which comes in a powder that is mixed with […]
read more

share

Related Posts


Amylin, Lilly Update On FDA Review Of BYETTA(R) (exenatide) Injection Monotherapy Submission

Health : Medical News Today

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) is continuing with its review of the regulatory application for use of BYETTA(R) (exenatide...

Does Long-Term Use of Byetta & Victoza Worsen Your Own Insulin Production?

Diseases & Conditions / Diabetes : Diabetes Daily

GLP-1 drugs are a category of drugs used primarily to treat type 2 diabetes, but can also be used in type 1 diabetes. Brand names of GLP-1 drugs include Byetta, Victoza, and Bydureon. GLP-1 is a “chemical messenger,” explains Gary S...

Exenatide (Byetta) Has Rapid, Powerful Anti-inflammatory Effect

Health : Newswise Medical News

Exenatide, a drug commonly prescribed to help patients with type 2 diabetes improve blood sugar control, also has a powerful and rapid anti-inflammatory effect, a University at Buffalo study has shown.

Byetta (exenatide) Approved In Combination With Glargine For Type 2 Diabetes

Health : Medical News Today

Byetta (exenatide) injection has been approved by the FDA as add-on treatment for use with insulin glargine, together with exercise and diet for diabetes type 2 patients who are not responding well enough to glargine alone. Byetta's...

Intarcia Therapeutics, Inc. Commences Enrollment Of ITCA 650 Phase 2 Study In Type 2 Diabetes

Health : Medical News Today

Intarcia Therapeutics, Inc. announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous delivery of exenatide) with Byetta, an FDA-approved twice-daily injection form of ...

Comments


Copyright © 2016 Regator, LLC